tbuckley/cabot-search huggingface dataset:
Elder abuse and neglect. Council on Scientific Affairs
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rome III criteria for functional gastrointestinal disorders: too much overlap to be useful?
Authors: A. C. Ford, D. Morgan, P. Moayyedi
Journal: Gut (2011)

<h3>Introduction</h3> Functional gastrointestinal (GI) symptoms are common. The Rome III classification of these symptoms into mutually exclusive disorders attempts to improve the homogeneity of patients recruited into clinical trials from secondary and tertiary care. Previous investigators have reported significant degrees of overlap between some of these conditions, but no study has examined this issue in its entirety. <h3>Methods</h3> This was a cross-sectional survey of consecutive new patients consulting a Gastroenterologist at two tertiary care centres. All individuals were provided with the self-administered, validated, Rome III diagnostic questionnaire for the adult functional GI disorders. We scored completed questionnaires according to the algorithm devised by the authors, but suspended the mutual exclusivity between various syndromes, such as dyspepsia, irritable bowel syndrome and functional constipation, required by the questionnaire in order to examine the degree of overlap between them. <h3>Results</h3> A total of 1822 patients completed the questionnaire. There were 1253 (68.8%) who met criteria for at least one of the functional GI disorders and 880 (70.2%) of these patients met criteria for more than one disorder when the mutual exclusivity was suspended. The degree of overlap between the various disorders varied between 3% and 86% and was greatest for functional vomiting and chronic idiopathic nausea (table 1). <h3>Conclusion</h3> The degree of overlap between the various Rome III diagnostic was variable but large in some cases. The magnitude of this overlap was of remarkably similar magnitude in some instances. These data suggest that some of these disorders have similar aetiologies or pathogenetic mechanisms and that attempts to classify them separately may be both artificial and futile.
Poisons: Their Isolation and Identification
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: The LARCID trial.
Authors: Paulo Marcelo Hoff, Daniel Fernandes Saragiotto, Carlos H. Barrios, Auro Del Giglio, Anelisa Kruschewsky Coutinho, Aline C Andrade, Carolina Dutra, Nora Forones, Mariangela Correa, Maria Socorro Portella, Vanessa Q. Passos, Renata N Chinen, Brigitte van Eyll
Journal: Journal of Clinical Oncology (2012)

549 Background: Chemotherapy-induced diarrhea (CID) is a relatively common adverse event in the treatment of colorectal cancer patients. The LARCID trial evaluated the efficacy and safety of long-acting release octreotide (octreotide LAR) for the prevention of CID in this population. Methods: Colorectal cancer patients starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil (5-FU), capecitabine and/or irinotecan were randomized to receive octreotide LAR, 30 mg intramuscularly every 4 weeks, (experimental arm) or the physician’s treatment of choice in case of diarrhea (control arm). Results: A total of 139 patients were randomized, most of which received 5-FU- and oxaliplatin-containing chemotherapy regimens. The rate of diarrhea was 76.1% in the experimental group (n=68) and 78.9% in the control group (n=71). Treatment with octreotide LAR did not prevent nor reduced the severity of CID. Treatment choices for diarrhea management included loperamide in the majority of cases. No benefit from octreotide LAR was identified in terms of need for diarrhea treatment, opioids, or intravenous hydration, nor in the rate of hospitalization, or quality-of-life. Conclusions: Octreotide LAR is not indicated for the prevention of CID.
Postmarketing surveillance
Authors: S Voss, F Harris
Journal: BMJ (1994)

leprosy.I referred him to the panel of leprosy opinion, which is a panel of experts appointed by the Department of Health to give advice on the clinical management of leprosy.More importantly, Crawford referred to a meeting between the parliamentary secretary for health and the Thalidomide Action Group.At that meeting Baroness Cumberlege undertook to make known to the medical profession the fact that guidelines on the use of thalidomide are available.Guidance on thalidomide was published in the May issue of Current Problems,2 which is distri- buted to most doctors.This guidance note advises all doctors considering using thalidomide to follow a guideline for the clinical use and distribution of thalidomide,3 which is available from Dr
Abstract 972: Direct observation in living tumors shows macrophage-dependent induction and dissemination of cancer stem cells in breast cancer
Authors: Ved P. Sharma, Yarong Wang, Binwu Tang, George S. Karagiannis, Emily A. Xue, David Entenberg, Lucia Borriello, Anouchka Coste, Chinmay R. Surve, Dominic Esposito, Maja H. Oktay, Lalage M. Wakefield, John S. Condeelis
Journal: Cancer Research (2019)

Abstract Cancer stem cells (CSCs) play an important role during metastatic progression of breast cancer. However, the in vivo properties and dynamic behavior of CSCs are not well understood. Here, we employed high-resolution intravital multiphoton microscopy using a SOX2/OCT4 responsive fluorescent stem cell biosensor to directly observe CSC dynamics in the living animal using an orthotopic breast cancer xenograft model. We report that CSCs constitute a minority population (1-3%) in the primary tumors, and display the slow-migratory, invasive phenotype that is specifically associated with disseminating tumor cell population. We also report, for the first time, that CSCs are preferentially localized in direct contact with macrophages near and in tumor microenvironment of metastasis (TMEM) sites, the macrophage-containing intravasation doorway for tumor cells and that CSCs metastasize to lung and are strikingly enriched in early lung metastatic colonies. This is explained by our observation that, in vitro and in vivo, direct physical contact with macrophages induces stemness in non-stem cancer cells via juxtacrine Notch-Jagged1 signaling. These data indicate for the first time that macrophages play an actively inductive role in the CSC niche and promote TMEM-mediated CSC intravasation and early metastatic seeding. Citation Format: Ved P. Sharma, Yarong Wang, Binwu Tang, George S. Karagiannis, Emily A. Xue, David Entenberg, Lucia Borriello, Anouchka Coste, Chinmay R. Surve, Dominic Esposito, Maja H. Oktay, Lalage M. Wakefield, John S. Condeelis. Direct observation in living tumors shows macrophage-dependent induction and dissemination of cancer stem cells in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 972.
SOCIETY PROCEEDINGS.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vacation Lectures on Fibrinous Deposition in the Heart: Its History and Practical Meaning
Authors: B. W. Richardson
Journal: BMJ (1860)

main truss, etc., and one or other of these contrivances gene- rally gives sufficient relief for the patient's comfort.But I have found it necessary to have recourse to more active measures than these, and to adopt operative treatment in three of the cases which have presented themselves during the present session.The circumstances for which operation may be and has been practised, in these and similar cases, can be arranged in the four following categories:-
Book Review Treatment of Diseases in Infants and Children . By Hans Kleinschmidt, M.D., Professor of Pediatrics, University of Hamburg. Authorized translation of the Fifth German Edition with additions, by Harry M. Greenwald, M.D., attending Pediatrician to the United Israel Zion Hospital; Consulting Physician to the Hebrew Infant Home of Brooklyn, Brooklyn, N. Y., Philadelphia, P. Blakiston's Son &amp; Co.
Journal: New England Journal of Medicine (1928)
The Cochrane Collaboration
Authors: Lisa Bero
Journal: JAMA (1995)

WHERE SHOULD a physician look to find accurate, up-to-date information about the effectiveness of a variety of clinical interventions? At the bedside or in the office, physicians should have instantaneous, up-to-date assistance from an affordable, universally available database of systematic reviews of the best evidence from clinical trials. Unfortunately, the physician who tries to seek the best evidence is often thwarted. Textbooks and reviews are often unreliable and years out of date.<sup>1</sup>The searcher may find the MEDLINE database, surely one of the greatest achievements of US medicine, daunting and incomplete. Although well over 1 million clinical trials have been conducted, hundreds of thousands remain See also pp 1942 and 1962. unpublished or are hard to find and may be in various languages. In the unlikely event that the physician finds all the relevant trials of a treatment, these are rarely accompanied by any comprehensive systematic review attempting to
Whatever happened to the chief complaint?
Authors: J. E. Harrison
Journal: JAMA (1981)

Some changes in medicine are good—some are not. Some changes are perceptible—some are not. New advances, new drugs, new treatments replace the old. Tried and unproved methods of diagnosis or treatment quietly fade away. The problem list and problem-oriented notes are useful additions to the proved and traditional methods of gathering and recording data. The format of chief complaint, present illness, past history, family history, review of systems, and physical examination has remained unchanged for many years. However, something insidious and disturbing is happening to the chief complaint. We are taught to ask the patient, "What's the main thing that's bothering you?"; "Why did you come to see the doctor?"; "What's the major problem that brought you to the hospital?". We then record the chief complaint in the patient's own words: "My chest hurts"; "My eyes itch"; "My period is late"; "I'm tired all the time"; "I believe I'm losing
Deaths from Chronic Renal Disease in U.S. Battery and Lead Production Workers
Authors: W. Clark Cooper
Journal: Environmental Health Perspectives (1988)

This report is based on an analysis of deaths in 4519 battery plant workers and 2300 lead production or smelter workers during the years 1947 to 1980. Causes were coded to the seventh (1955) revision of the International Classification of Diseases. There were significant excess deaths for "other hypertensive disease" (444-447) and "chronic nephritis" (592-594) in both cohorts, the standardized mortality ratios (SMRs) being 320 and 475, respectively, for the former causes and 222 and 265 for the latter. Proportionate mortality analysis, which adjusted for race, also showed elevated ratios, 241 and 388 for the former causes and 296 and 186 for the latter. Deaths from other hypertension-related diseases did not show comparable excesses. Renal cancer deaths were fewer than expected, SMRs being 41 and 74, respectively.
History Taking and Recording.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SOME POINTS ON TRACHEOTOMY
Authors: W. W. DAWSON
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Anatomy of the Eye and Orbit Including the Central Connections, Development, and Comparative Anatomy of the Visual Apparatus
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis
Authors: C. Brun-Buisson
Journal: JAMA (1995)

<h3>Objective.</h3> —To examine the incidence, risk factors, and outcome of severe sepsis in intensive care unit (ICU) patients. <h3>Design and Setting.</h3> —Inception cohort study from a 2-month prospective survey of 11 828 consecutive admissions to 170 adult ICUs of public hospitals in France. <h3>Patients.</h3> —Patients meeting clinical criteria for severe sepsis were included and classified as having documented infection (ie, documented severe sepsis, n=742), or a clinical diagnosis of infection without microbiological documentation (ie, culture-negative severe sepsis, n=310). <h3>Main Outcome Measures.</h3> —Hospital and 28-day mortality after severe sepsis. <h3>Results.</h3> —Clinically suspected sepsis and confirmed severe sepsis occurred in 9.0 (95% confidence interval [CI], 8.5 to 9.5) and 6.3 (95% CI, 5.8 to 6.7) of 100 ICU admissions, respectively. The 28-day mortality was 56% (95% CI, 52% to 60%) in patients with severe sepsis, and 60% (95% CI, 55% to 66%) in those with culture-negative severe sepsis. Major determinants of both early (&lt;3 days) and secondary deaths in the whole cohort were the Simplified Acute Physiology Score (SAPS) II and the number of acute organ system failures. Other risk factors for early death included a low arterial blood pH (&lt;7.33) (<i>P</i>&lt;.001) and shock (<i>P</i>=.03), whereas secondary deaths were associated with the admission category (<i>P</i>&lt;.001), a rapidly or ultimately fatal underlying disease (<i>P</i>&lt;.001), a preexisting liver (<i>P</i>=.01) or cardiovascular (<i>P</i>=.002) insufficiency, hypothermia (<i>P</i>=.02), thrombocytopenia (<i>P</i>=.01), and multiple sources of infection (<i>P</i>=.02). In patients with documented sepsis, bacteremia was associated with early mortality (<i>P</i>=.03). <h3>Conclusions.</h3> —Only three of four patients presenting with clinically suspected severe sepsis have documented infection. However, patients with clinically suspected sepsis but without microbiological documentation and patients with documented infection share common risk factors and are at similarly high risk of death. In addition to the severity of illness score, acute organ failures and the characteristics of underlying diseases should be accounted for in stratification of patients and outcome analyses. (<i>JAMA</i>. 1995;274:968-974)
THE SOCIAL RESPONSIBILITIES OF MODERN MEDICINE
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies
Authors: T. Urban, B. Lebeau
Journal: European Respiratory Journal (1999)

Racemic R,S-salbutamol is taken to relieve bronchial constriction. Only the R-enantiomer has bronchodilating properties. The S-enantiomer has been proposed to cause in vitro bronchial hyperreactivity in guinea-pigs. Stereoselective elimination of salbutamol has been shown, with S-salbutamol being eliminated at a slower rate than R-salbutamol. This study questioned whether rates of stereoselective elimination were similar after oral or lung delivery, and whether the S:R ratio would increase after repeated inhalations in a situation resembling a common clinical use. Eighteen healthy volunteers received single-dose racemic salbutamol as a solution instilled in the trachea during anaesthesia, as inhaled micronized powder and/or as ingested tablets. Five volunteers inhaled repeated doses of racemic salbutamol. Concentrations in plasma and urine were measured using a technique which allowed chiral separation of samples with concentrations as low as 0.1 ng x mL(-1). The bioavailability of S-salbutamol was significantly higher than that of R-salbutamol after the different modes of administration. Stereoselective elimination was more pronounced after oral administration than after inhalation. Repeated inhalations resulted in successive increases in the S:R ratio as steady state was approached. In conclusion, the clinical consequences of increasing plasma concentrations of S-salbutamol need to be further assessed.